190 related articles for article (PubMed ID: 15714988)
21. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy.
Pandha H; Eaton J; Greenhalgh R; Soars D; Dalgleish A
Cancer Gene Ther; 2005 Jun; 12(6):572-8. PubMed ID: 15803141
[TBL] [Abstract][Full Text] [Related]
22. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
23. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.
Timme TL; Hall SJ; Barrios R; Woo SL; Aguilar-Cordova E; Thompson TC
Cancer Gene Ther; 1998; 5(2):74-82. PubMed ID: 9570298
[TBL] [Abstract][Full Text] [Related]
24. Current progress in suicide gene therapy for cancer.
Yazawa K; Fisher WE; Brunicardi FC
World J Surg; 2002 Jul; 26(7):783-9. PubMed ID: 11948367
[TBL] [Abstract][Full Text] [Related]
25. [Gene therapy of tumors, state of the art and prospects].
Lollini PL
Pathologica; 2001 Dec; 93(6):625-30. PubMed ID: 11785112
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for ovarian cancer (review).
Wolf JK; Jenkins AD
Int J Oncol; 2002 Sep; 21(3):461-8. PubMed ID: 12168087
[TBL] [Abstract][Full Text] [Related]
27. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy.
Loimas S; Toppinen MR; Visakorpi T; Jänne J; Wahlfors J
Cancer Gene Ther; 2001 Feb; 8(2):137-44. PubMed ID: 11263529
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound.
Aoi A; Watanabe Y; Mori S; Takahashi M; Vassaux G; Kodama T
Ultrasound Med Biol; 2008 Mar; 34(3):425-34. PubMed ID: 18096302
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
30. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
Hall SJ; Sanford MA; Atkinson G; Chen SH
Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
[TBL] [Abstract][Full Text] [Related]
31. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
32. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
33. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models.
Mizuno M; Ryuke Y; Yoshida J
Cancer Gene Ther; 2002 Oct; 9(10):825-9. PubMed ID: 12224023
[TBL] [Abstract][Full Text] [Related]
34. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
35. [Adenovirus-mediated interleukin-12 gene therapy for prostate cancer].
Nasu Y; Ebara S; Kumon H
Nihon Rinsho; 2004 Jun; 62(6):1181-91. PubMed ID: 15206161
[TBL] [Abstract][Full Text] [Related]
36. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
[TBL] [Abstract][Full Text] [Related]
37. [Gene therapy for malignant brain tumors--the present conditions and the prospects].
Nakahara N; Yoshida J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():499-503. PubMed ID: 16201571
[No Abstract] [Full Text] [Related]
38. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
39. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
40. Combine cancer gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and Herpes simplex thymidine kinase suicide gene.
Pastorakova A; Hlubinova K; Jakubikova J; Altaner C
Neoplasma; 2006; 53(5):353-62. PubMed ID: 17013529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
